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Background: We retrospectively analyzed castration-resistant prostate cancer (CRPC) patients treated
with secondary hormonal therapies (SHTs) prior to docetaxel therapy.
Methods: The cases of 73 CRPC patients who underwent docetaxel therapy in 2005e2011 at four
hospitals in Ibaraki, Japan were analyzed. We determined the cause-speciﬁc survival (CSS) from the start
of docetaxel therapy and the time point of CRPC diagnosis, and we compared the CSS achieved with/
without prior classical SHTs, which were deﬁned as low-dose steroid and estramustine phosphate.
Results: Of the 73 enrolled patients, 26 underwent docetaxel therapy (DOC group), and 47 underwent
SHTs (SHTs-DOC group) as the initial treatment for CRPC. In the docetaxel therapy, the rate of prostate-
speciﬁc antigen responses were higher in the DOC group compared with the SHTs-DOC group (76.9% vs.
44.7%, P ¼ 0.0066). The median CSS from the docetaxel therapy initiation was not signiﬁcant but longer
in the DOC group than in the SHTs-DOC group (23.4 months vs. 16.6 months, P ¼ 0.0969). However, the
median CSS from the time of CRPC diagnosis did not signiﬁcantly differ between the DOC and SHTs-DOC
groups (23.4 months vs. 24.7 months, P ¼ 0.9233). In a univariate analysis, pain and visceral metastasis
appeared to be risk factors for the CSS in the SHTs-DOC group. The patients with pain and/or visceral
metastasis had signiﬁcantly poorer survival than those without these factors in the SHTs-DOC group
(31.5 months vs. 16.8 months, P ¼ 0.0053).
Conclusion: The induction of SHTs prior to docetaxel therapy is an acceptable treatment option with
some survival beneﬁts for CRPC patients without pain and visceral metastases.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Among men in Western industrialized countries, prostate can-
cer (PC) is themost frequently diagnosedmalignant disease and the
second leading cause of cancer-speciﬁc mortality.1 In Japan, the
incidence of PC has markedly increased in recent years, and 21% ofaraki Clinical Education and
ukuba, c/o Ibaraki Prefectural
-1793, Japan.
imazui).
ciﬁc Prostate Society, Published bPC patients present with distant metastases; 19% present with
locally advanced disease at diagnosis.1,2 With this high incidence of
advanced disease, androgen-deprivation therapy (ADT) is a main-
stay of treatment for locally advanced and metastatic PC. ADT is
reported to be effective for < 3e5 years as an average interval,3,4
but cases of castrated PC eventually transform into castration-
resistant PC (CRPC).
Docetaxel, which is the current standard ﬁrst-line chemother-
apeutic agent for CRPC, has shown survival and palliative beneﬁts
in the TAX327 and the Southwest Oncology Group 99-16 studies.5,6
Several new agents such as abiraterone, enzalutamide, andy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
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Phase 3 trials.7e11 However, the optimal sequencing of treatment
for CRPC patients has not yet been established.
The classical secondary hormonal therapies (SHTs) such as
corticosteroids and estramustine phosphate (EMP) are described as
options for ﬁrst-line systemic therapy for CRPC without visceral
metastases in the National Comprehensive Cancer Network Clinical
Practice Guidelines for Prostate Cancer, version 1.2015.12 However,
Armstrong et al13 demonstrated that the prior use of EMP is a risk
factor for the survival of CRPC patients undergoing docetaxel
therapy. Although there is insufﬁcient data supporting the classical
SHTs as ﬁrst-line systemic therapy for CRPC, it may be true that the
majority of CRPC patients should be administered docetaxel ther-
apy prior to SHTs before receiving any of the emerging new agents
in Japan.
Therefore, in the present study we investigated whether clas-
sical SHTs could affect the response to docetaxel therapy and the
survival of CRPC patients. We also analyzed the clinical factors that
could be used to determine whether or not classical SHTs are
feasible prior to docetaxel therapy in CRPC patients.Table 1
Baseline characteristics of the 73 patients with castration-resistant prostate
cancer (CRPC).
DOC group
(n ¼ 26)
SHTs-DOC group
(n ¼ 47)
P
Age (y)
Median 68.0 70.0 0.3681
Range 39e81 54e83
Gleason score > 7 (%) 83.3 86.1 0.7370
Prior treatment (%)
Alternative anti-androgen 69.2 89.4 0.0527
Antiandrogen withdrawal 84.6 70.2 0.2575
ECOG performance status (%)
0e1 96.2 89.4 0.4118
2 3.8 10.6
Pain (%) 34.6 21.3 0.2685
Serum PSA (ng/mL)
Median 42.0 26.5 0.5189
Range 2.24e2379 2.43e924
Anemia, % (Hb < 12 g/dL) 50.0 31.0 0.1319
ALP (U/L)
Median 310 331 0.9049
Range 164e4061 146e2789
Extent of disease (%)
Bone metastasis 73.1 78.7 0.5783
Visceral metastasis 19.2 10.6 0.3140
PSADT (mo) 1.04 1.30 0.2199
0.01e7.38 0.02e10.72. Materials and methods
2.1. Patients
Between 2005 and 2011, a total of 73 patients who received
docetaxel therapy at four hospitals in Ibaraki prefecture, Japanwere
enrolled in this multi-institution retrospective cohort study. The
eligible patients had histologically conﬁrmed adenocarcinoma of
the prostate, as clinically diagnosed CRPC. The Prostate Cancer
Clinical Trials Working Group advises classifying tumors that are
progressing with castration levels of testosterone as “castration-
resistant”.14 We deﬁned CRPC by disease progression after the
administration of ADT, because the serum levels of testosterone of
some patients were not measured. Disease progressionwas deﬁned
by prostate-speciﬁc antigen (PSA) progression or by radiographic
imaging studies. PSA progression was deﬁned as an increase
by  25% in serum PSA (at least 2 ng/mL) from the nadir value.
We evaluated the results of the patients' radiographic imaging
studies using the Response Evaluation Criteria in Solid Tumors
version 1.1. We excluded the patients who had prior treatment with
cytotoxic agents other than EMP from this study. To analyze the
differences in CRPC treatment types, we divided the patients into
two groups. The patients who underwent docetaxel therapy as the
initial treatment for CRPC were classiﬁed as the DOC group. After
the initial docetaxel therapy, these patients underwent other
treatment, e.g., with SHTs, other chemotherapy, and best support-
ive care. The patients who underwent docetaxel therapy after
classical SHTs were classiﬁed as the SHTs-DOC group.
The data at the diagnosis of CRPC included the patient's age,
performance status, presence of pain, laboratory evaluations (he-
moglobin, alkaline phosphatase, and PSA), and site of metastases.
The follow-up status data were collected in March 2016. The me-
dian duration of follow-up was 23.4 months (range,
1.53e101.2 months). The institutional review board of four hospi-
tals approved this study, as the registry form was anonymous.Time from starting PADT to CRPC (mo)
Median 15.7 23.3 0.1313
Range 3.0e134.1 6.1e163.5
Alive (%) 15.4 4.3 0.1775
Dead (%) 84.6 95.7
Cancer/other causes (%) 73.1/11.5 95.7/0
ALP, alkaline phosphatase; DOC, docetaxel; ECOG, Eastern Cooperative Oncology
Group; Hb, hemoglobin; PADT, primary androgen deprivation therapy; PSA,
prostate-speciﬁc antigen; PSADT, PSA doubling time; SHTs, secondary hormonal
therapies.2.2. Evaluation of PSA doubling time
The PSA doubling time (PSADT) was deﬁned as the time
required for the PSA level to double. The PSADT was estimated
according to the following formula:
PSADT ¼ ln2  T/[ln(PSA2)  ln(PSA1)] (1)where ln is the natural log, and T is the number of months between
two consecutive PSA determinations (PSA1 and PSA2).15 PSA1 is the
value at the time of the diagnosis of CRPC, and PSA2 is the value at
the start of the initial treatment for CRPC. The PSADTs were
determined by twomeasurements of the PSA value at least 4 weeks
apart.
2.3. Treatment
The docetaxel therapy was given in a regimen of every 3 weeks
docetaxel (70e75 mg/m2) based on the schedule reported by
Tannock et al,5 and 5-mg prednisone was generally administered
twice daily. The adjustment of the treatment schedule and any dose
reduction in docetaxel therapy were determined by the treating
physician's recommendation. The agent of classical SHTs was
deﬁned as low-dose steroid (prednisone 10 mg/d or dexametha-
sone 0.5e1.5 mg/d) and EMP.
2.4. Statistical analysis
The primary objective of this study was deﬁned as the cause-
speciﬁc survival (CSS) after either the induction of docetaxel ther-
apy or the time point of the diagnosis of CRPC between the SHTs-
DOC group and the DOC group. Survival curves were constructed
using the KaplaneMeier method, and the difference between the
curves was evaluated using the Log Rank test. As the secondary
objective, we analyzed prognosis-related risk factors in the SHTs-
DOC group with univariate and multivariate analysis using Cox's
proportional hazards model and the Log Rank test. We selected the
known prognostic factors for multivariate analysis with the
Fig. 1. Analysis of prostate-speciﬁc antigen (PSA) responses and cause-speciﬁc survival (CSS) following docetaxel therapy. (A) PSA responses [> 50% PSA decline compared with
pretreatment PSA following docetaxel (DOC) therapy] and (B) CSS from the start of DOC therapy in the DOC group and secondary hormonal therapies (SHTs)-DOC group. * Sta-
tistically signiﬁcant difference (P < 0.05). pts., patients.
Fig. 2. KaplaneMeier estimates of cause-speciﬁc survival (CSS) in the secondary
hormonal therapies-docetaxel (SHTs-DOC) group and DOC group. CRPC, castration-
resistant prostate cancer.
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tients and were not confounder with the variables detected by
univariate analysis. We then investigated the differences in the CSS
from the time point of the diagnosis of CRPC classiﬁed by a com-
bination of signiﬁcant factors according to the above statistics.
Additionally, we analyzed the difference in PSA responses between
the DOC group and the SHTs-DOC group by Fisher's exact test. “PSA
response” was deﬁned as a > 50% decline following docetaxel
therapy compared with the pretreatment PSA. Differences between
the two patient groups in baseline characteristics were analyzed
with the Chi-square test or Wilcoxon rank sum test. A probability
(P) value < 0.05 was considered signiﬁcant.
3. Results
3.1. Patient characteristics
Among the 73 enrolled patients, 26 patients underwent doce-
taxel therapy (the DOC group), and 47 patients underwent SHTs
(the SHTs-DOC group) as the initial treatment for CRPC. The char-
acteristics of the enrolled patients are summarized in Table 1. Most
of the patients in this cohort undertook an alternative antiandrogen
therapy and antiandrogen withdrawal. No signiﬁcant difference in
patient characteristics was observed between the DOC and SHTs-
DOC groups.
3.2. Analysis of PSA responses and CSS following docetaxel therapy
The PSA responses to docetaxel therapy were signiﬁcantly
higher in the DOC group compared with the SHTs-DOC group
(76.9% vs. 44.7%, P ¼ 0.0066; Fig. 1A). Moreover, the median CSS
from starting docetaxel therapy was longer in the DOC group than
that in the SHTs-DOC group, but the difference was not signiﬁcant
(23.4 months vs. 16.6 months, P ¼ 0.0969; Fig. 1B).
3.3. Analysis of CSS from time of diagnosis of CRPC
The median CSS from the time of diagnosis of CRPC was not
signiﬁcantly different between the two groups (DOC group
23.4 months, SHTs-DOC group 24.7 months, P¼ 0.9233; Fig. 2). The
univariate analysis to analyze the prognosis-related risk factors in
the SHTs-DOC group identiﬁed visceral metastasis and pain assigniﬁcant factors associated with CSS (Table 2). There were no
signiﬁcant prognosis-related risk factors in multivariate analysis,
but the hazard ratio of visceral metastasis and pain was still higher
compared with the other factors.
The following statistics with risk classiﬁcation, assessed by
visceral metastasis and/or pain in the SHTs-DOC group, demon-
strated that the median CSS form the diagnosis of CRPC was sig-
niﬁcant shorter in the high-risk group compared with the low-risk
group (16.8 months vs. 31.5 months, P ¼ 0.0053; Fig. 3). In low-risk
group, the median CSS from the time of diagnosis of CRPC was not
signiﬁcantly different between the DOC group and SHTs-DOC group
(31.5 months vs. 31.5 months, P ¼ 0.9139; data not shown).
4. Discussion
Docetaxel-based chemotherapy showed a survival beneﬁt for
CRPCpatients in the TAX327 and the SouthwestOncologyGroup 99-
16 studies.5,6 Although the efﬁcacy of the new agents for CRPC has
been demonstrated in recent years, docetaxel is still standard as a
ﬁrst-line chemotherapy agent for CRPC patients. However, there is
no high-level evidence regarding which type(s) of patients with
CRPC should be administered docetaxel-based chemotherapy
Table 2
The univariate and multivariate analysis of prognostic factors in the secondary hormonal therapies-docetaxel group.
n Cox proportional hazard model
(univariate)
Log-rank test Cox proportional hazard model
(multivariate)
HR 95% CI of HR P P HR 95% CI of HR P
Age > 70 y 47 1.46 0.78e2.71 0.2318 0.2272 1.42 0.74e2.74 0.2959
ECOG performance status 2 47 0.98 0.34e2.28 0.9623 0.9624 0.87 0.25e2.43 0.8072
Gleason score > 7 43 1.00 0.45e2.68 0.9876 0.9876
PSA > 100 ng/mL 46 0.82 0.37e1.64 0.5864 0.5928
PSADT < 1.3 mo 43 1.52 0.81e2.86 0.1902 0.1857
Anemia (Hb < 12g/dL) 42 0.73 0.39e1.40 0.3450 0.3410
ALP > 700 U/mL 38 1.23 0.36e3.16 0.7022 0.6942
Bone metastasis 47 1.69 0.82e3.94 0.1611 0.1781
Visceral metastasis 47 3.27 1.09e8.05 0.0365* 0.0120* 1.94 0.49e6.64 0.3274
Pain 47 1.45 0.81e2.51 0.0638 0.0451* 1.90 0.65e5.37 0.2369
Time from starting PADT to CRPC < 24 mo 47 0.85 0.46e1.55 0.5919 0.5914 0.89 0.47e1.7 0.7294
ALP, alkaline phosphatase; CI, conﬁdence interval; CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HR, hazard ratio;
PADT, primary androgen deprivation therapy; PSA, prostate-speciﬁc antigen; PSADT, PSA doubling time.
* Statistically signiﬁcant difference (P < 0.05).
Fig. 3. KaplaneMeier estimates of cause-speciﬁc survival (CSS) according to risk group
classiﬁcation in the secondary hormonal therapies-docetaxel (SHTs-DOC) group. CRPC,
castration-resistant prostate cancer. * Statistically signiﬁcant difference (P < 0.05).
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the patients with prior SHTs was shorter than that of the patients
withoutprior SHTs, the initial treatment bydocetaxel or SHTsdidnot
result in a signiﬁcant difference in CSS from the diagnosis of CRPC.
Song et al16 also assessed the efﬁcacy of initial treatment in 384
CRPC patients by EMP, docetaxel, and mitoxantrone in Korea, and
they found that the overall survival from the start of the initial
treatment for CRPC was not signiﬁcantly different among these
initial treatments. Therefore, there might be survival beneﬁts of
classical SHTs as initial treatment for at least some Asian CRPC
patients in clinical practice.
The recent use of AR-axis-targeted (ARAT) therapies, such as
abiraterone and enzalutamide, provided improved survival in pa-
tientswithmetastatic CRPCwho received prior docetaxel treatment
and in those who were chemotherapy-naïve.8,10 These clinical ben-
eﬁts of ARAT therapies have been shown in trials of asymptomatic or
minimally symptomatic patients. In a systemic review of CRPC
treatment, Chi et al17 suggested the following treatment algorithm
for CRPC patients based on prospective/retrospective data and
clinical experiences. In their algorithm,ARAT therapies are preferred
for patients without the following clinical characteristics: prior ADT
response of < 1 year, symptomatic disease, or visceral disease.
In the present study, the median CSS achieved by administering
classical SHTs prior to docetaxel was signiﬁcantly longer in theCRPC patients who did not have pain and visceral metastases. CRPC
is not curable, and so therapeutic strategies should be considered
from a viewpoint of optimizing a patient's quality of life (QOL). We
could not compare QOL between the DOC group and SHTs-DOC
group in this retrospective study. However, the prechemotherapy
phase is important because the adverse events of chemothera-
peutic agents such as docetaxel and cabazitaxel reduce a patient's
QOL. We thus speculate that SHTs including ARAT therapies are
suitable for treating CRPC patients without pain and visceral me-
tastases, particularly in Asian patients including Japanese. In clas-
sical SHTs, estrogen agents such as EMP and diethylstilbestrol are
associated with cardiovascular and thromboembolic complica-
tions.18,19 Notably, ARAT therapies are more than 10 times as
expensive as classical SHTs in Japan.
The limitations of this study are that it was a retrospective study
with a small sample size, and the heterogeneous background of the
patients. Missing laboratory data may have inﬂuenced the results.
In some patients, we were not able to determine whether the in-
clusion criteria for the CRPC deﬁnition were fulﬁlled because the
serum level of testosterone was not checked. The patients in this
study were treated upon their clinician's recommendation.
Furthermore, we could not assess the measurements of patient's
QOL in this cohort. A prospective study would be necessary to
resolve these limitations in future studies.
In conclusion, the early administration of docetaxel improved
the PSA response of CRPC patients and their survival after starting
docetaxel therapy, but a signiﬁcant difference in survival after the
diagnosis of CRPC was not observed between the patients with
early and late initiation of docetaxel therapy. Moreover, there was
good survival outcome in the patients without pain and visceral
metastases, even among those treated by classical SHTs prior to
docetaxel.
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